ERBB2 and breast cancer: Of patients with HR+/HER2−, HR+/HER2+, HR−/HER2+ (HER2-overexpressing), and HR−/HER2− (triple negative) breast cancer, 33.1% (10,712/32,376), 33.1% (1912/5768), 29.6% (850/2875), and 27.7% (1689/6104) received immediate breast reconstruction surgery (chi-square test, P < 0.001), respectively.